PRPH Quote, Financials, Valuation and Earnings

Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 12.56%. ProPhase Labs's return on equity of -59.59% beat Fonar's return on equity of 6.13%.

ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2930.3%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

ProPhase Labs has a beta of -0.316, which suggesting that the stock is 131.62% less volatile than S&P 500. In comparison Fonar has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.004%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than Fonar quarterly revenues of $25M. ProPhase Labs's net income of -$6.6M is lower than Fonar's net income of $3.1M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 10.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.89x versus 0.95x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -11733.04%. ProPhase Labs's return on equity of -59.59% beat OncoCyte's return on equity of -211.42%.

ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2930.3%. On the other hand OncoCyte has an analysts' consensus of -- which suggests that it could grow by 86.65%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

ProPhase Labs has a beta of -0.316, which suggesting that the stock is 131.62% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.608%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are larger than OncoCyte quarterly revenues of $115K. ProPhase Labs's net income of -$6.6M is higher than OncoCyte's net income of -$13.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.89x versus 33.60x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 13.08%. ProPhase Labs's return on equity of -59.59% beat Veracyte's return on equity of -0.84%.

ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2930.3%. On the other hand Veracyte has an analysts' consensus of -- which suggests that it could grow by 5.7%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

ProPhase Labs has a beta of -0.316, which suggesting that the stock is 131.62% less volatile than S&P 500. In comparison Veracyte has a beta of 1.690, suggesting its more volatile than the S&P 500 by 69.047%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than Veracyte quarterly revenues of $115.9M. ProPhase Labs's net income of -$6.6M is lower than Veracyte's net income of $15.2M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.89x versus 7.29x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -56.4%. ProPhase Labs's return on equity of -59.59% beat XWELL's return on equity of -71.82%.

ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2930.3%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 357.52%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

ProPhase Labs has a beta of -0.316, which suggesting that the stock is 131.62% less volatile than S&P 500. In comparison XWELL has a beta of 2.426, suggesting its more volatile than the S&P 500 by 142.629%.

ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

ProPhase Labs quarterly revenues are $3.1M, which are smaller than XWELL quarterly revenues of $8.4M. ProPhase Labs's net income of -$6.6M is lower than XWELL's net income of -$4.8M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.89x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.